LAST INFORMATION 17.45 An experimental, personalized vaccine against cancer, developed by Merck and Moderna, recorded positive initial results in the first large-scale final phase study, the two companies announced on Wednesday, bringing it under development treatment a step closer to submitting an application for approval. The mRNA technology vaccine, combined with [...]